RSLS - Listing about to Churn Its Share Float after Receiving FDA PMA Supplement Approval

2023-12-13 08:20:13 ET

DENVER, Colo., Dec 13, 2023 ( www.247marketnews.com )- ReShape Lifesciences (NASDAQ: RSLS) stated, this morning, that the U.S. Food and Drug Administration (FDA) granted PMA supplement approval its next generation, enhanced Lap-Band 2.0 FLEX, and the Company is initiating its U.S. product launch.

ReShape Lifesciences is trading at $$0.3535, up $0.1025 (+40.84%), on 12.3M shares traded.

Its 52-week range is $0.1856 to $22.40. This is trading at two-month highs and is on track to eclipse its reported 13.01M shares in the float.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an …

The post Listing about to Churn Its Share Float after Receiving FDA PMA Supplement Approval appeared first on 24/7 Market News .

For further details see: